Tumor Vascular Therapy With TNF

[1]  S. Carlini,et al.  The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities , 1988, World Journal of Surgery.

[2]  A. Eggermont,et al.  Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion , 2003, British Journal of Cancer.

[3]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[4]  A. Eggermont,et al.  Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity , 2002, British Journal of Cancer.

[5]  A. Eggermont,et al.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras , 2002, British Journal of Cancer.

[6]  A. Eggermont,et al.  Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats , 2002, International journal of cancer.

[7]  A. Eggermont,et al.  Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions , 2000, British Journal of Cancer.

[8]  A. Eggermont,et al.  Low‐dose tumor necrosis factor‐α augments antitumor activity of stealth liposomal doxorubicin (DOXIL®) in soft tissue sarcoma‐bearing rats , 2000, International journal of cancer.

[9]  A. Eggermont,et al.  Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model , 2000, Journal of immunotherapy.

[10]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[11]  A. Eggermont,et al.  TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.

[12]  S. Mocellin,et al.  Soft tissue limb sarcomas , 1999, Cancer.

[13]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[14]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[15]  A. Eggermont,et al.  Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. , 1999, Oncology reports.

[16]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[17]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[18]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[19]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. K. Jain,et al.  Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. , 1996, British Journal of Cancer.

[21]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[22]  A. Eggermont,et al.  Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Ninfo,et al.  Phase II study on neoadjuvant hyperthermic‐antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas , 1994, Cancer.

[25]  N. Cascinelli,et al.  Treatment of primary or relapsing limb cancer by isolation perfusion with high‐dose alpha‐tumor necrosis factor, gamma‐interferon, and melphalan , 1994, Cancer.

[26]  J. Thomas,et al.  Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion , 1993 .

[27]  A. Eggermont,et al.  Treatment of Irresectable Soft Tissue Sarcomas of the Limbs by Isolation Perfusion with High Dose TNFα in Combination with Interferon-γ and Melphalan , 1993 .

[28]  R. Mirimanoff,et al.  Regional therapy of melanoma. , 1993, European journal of cancer.

[29]  G. Feifel,et al.  Optimization of isolated hyperthermic limb perfusion. , 1992, World journal of surgery.

[30]  J. Thompson,et al.  Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs , 1992, World journal of surgery.

[31]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  U. Tjaden,et al.  Chromatographic analysis of anticancer drugs. , 1990, Journal of chromatography.

[33]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[34]  B. Kroon,et al.  Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities , 1989, Cancer.

[35]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. V. van Geel,et al.  Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[38]  I. Hutton,et al.  Chemotherapy of sarcomas of the limbs by regional perfusion. , 1977, Annals of surgery.

[39]  B. Giovanella,et al.  Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion. , 1975, American journal of surgery.

[40]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.